有關台灣禮來公司糖尿病治療藥物GLP1-RA Dulaglutide(TRULICITY | injection 0.75mg/1.5mg)藥品事宜
本會於111年9月23日行文台灣禮來公司有關糖尿病治療藥物GLP1-RA Dulaglutide (TRULICITY injection 0.75mg/1.5mg)藥品事宜
111年9月27日台灣禮來公司回復本學會關切之糖尿病治療藥物GLP1-RA Dulaglutide 來文如下；
受文者:社團法人中華民國糖尿病學會
發文日期:中華民國 111 年9月27日
發文字號:北台禮字第 19121883 號
速別:最速件 密等及解密條件或保密期限:普通
主 旨:有關台灣禮來公司糖尿病治療藥物GLP1-RA Dulaglutide (TRULICITY injection 0.75mg/1.5mg,中文名稱:易週糖注射劑 0.75/1.5mg )藥品,市場供貨說明。
說明: ..
一、由於全球對 GLP-1 RA 的需求出現急速成長,造成易週糖(Trulicity®)供應不足影響產能排程,目前全球供貨吃緊,台灣市場預估2023 全年將面臨持續供貨不穩定的狀況。
二.我們盡全力減少對病患的影響,但仍預期病患將面臨易週糖處方中斷的情況,因此,我們已通知醫療人員暫停開立易週糖處方予新的病患,以便優先考慮現有病患的照顧,並請醫療人員依照其專業臨床判斷協助病患做最適當的藥物調整。
三、台灣禮來遵循相關規定向主管機關報備,期將影響降至最低。
四、 禮來總部持續監測並管理全球第2型糖尿病患者的供應需求,同時繼續投資擴充其製造產能,以提升全球供貨能力,我們希望能盡全力降低影響。
五、為病患提供安全、高品質的藥物是禮來公司最重要的使命,台灣禮來將持續向總部關心易週糖未來恢復供貨時間,並秉持我們照顧病患的承諾,持續致力創新藥品的研發,以及爭取相關藥物的供應穩定,以追求病患福祉為念。
Due to unprecedented demand increase among all GLP-1 RAs, the shortage of Trulicity® and capacity of product supply is impacted, and global supply is tight. Unstable supply in Taiwan is expected throughout 2023.
We are working to minimize the impact to patients but do anticipate some patients may experience a disruption in filling their prescription for Trulicity. We have requested that health care professionals not start any new patients on Trulicity so that existing patients can be prioritized. We also rely on health care professionals to make the best appropriate adjustment on patients' medication
Lilly Taiwan complies with regulatory guidelines in reporting relevant supply shortage issue to the health authority to reduce the impact to the minimum.
Eli Lilly is constantly monitoring and managing the supply needed of Type 2 diabetes patients and continues to invest and increase manufacturing, supply capacity globally to shorten the shortages and out of stock duration. We aim to lower the impact to the minimum.
Lilly is committed to manufacturing and providing safe, high-quality medicines for people who need them. Lilly Taiwan will stay in tuned with the headquarter on Trulicity's future restocking schedule. We will continue our dedication to the innovative research and development and strive for a stable drug supply to provide better Taiwan's medical quality and help more patients.